Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score®test: ...
Highlights From the 2025 Pediatric Oncology East and Mediterranean Biennial Conference: Advancing Pediatric Oncology Across the Eastern Mediterranean Breast cancer imposes a substantial disease burden ...
Genetic assays have transformed how clinicians approach treatment decisions in breast cancer, offering both predictive and prognostic insight that helps tailor therapy to individu ...
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early ...
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions The feasibility of Oncotype DX ...
Please provide your email address to receive an email when new articles are posted on . A novel AI multimodal model outperformed Oncotype DX in overall distant recurrence rate at 15 years. Additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results